Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click for my updated look at VIR ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

Functional cure of chronic hepatitis B (CHB) remains a major clinical challenge. Current therapies—including nucleos(t)ide ...

MDSCs are known to suppress immune responses in various diseases, including bacterial and fungal infections, through mechanisms such as the inhibition of T cell proliferation. In this study, we show ...

Symptoms, and Treatment Liver cancer is one of the most challenging forms of cancer, often developing quietly before showing any clear signs. It begins when abnormal cells form in the liver, a vital ...

When B cells are absent, FOXO1 levels drop and the T cells fail to develop into long-lasting memory cells. "Using the firefighter metaphor, vaccines are like a fire drill, meant to teach the immune ...

Hepatitis B is a highly infectious liver disease caused by the Hepatitis B virus (HBV) and is primarily transmitted through infected blood, bodily fluids, or childbirth. Although many cases are acute ...

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University Atlanta, Atlanta, Georgia 30322, United States ...

Chronic hepatitis B infection is primarily driven by persistence of HBV cccDNA and integration of HBV DNA into the human genome in liver cells, the primary source of hepatitis B surface antigen ...